Xenikos receives FDA Fast Track designation for T-Guard(R) for treating SR-aGVHD
Xenikos announced the FDA has granted Fast Track designation to T-Guard, Xenikos' flagship product designed to treat steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation. October 14, 2019